Bris­tol My­er­s' Op­di­vo fails part two of post-kid­ney can­cer surgery test as com­peti­tor Mer­ck touts new sur­vival da­ta

Op­di­vo failed the sec­ond part of a piv­otal study for post-surgery kid­ney can­cer, re­searchers re­port­ed on Sat­ur­day.

Bris­tol My­ers Squibb’s check­point in­hibitor failed to im­prove …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER